Parliamentary questions

Questions

TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work

Browse the questions

Clear

Showing questions asked by Ken O'Flynn .

3,835 questions match, newest first.

Ken O'Flynn Written 9 Jun 2026 · to Health
1833. Deputy Ken O'Flynn asked the Minister for Health whether any assessment has been undertaken regarding regional variation in SCAN eligibility decisions or referral acceptance practices. [41700/26]
Ken O'Flynn Written 9 Jun 2026 · to Health
1834. Deputy Ken O'Flynn asked the Minister for Health whether the forthcoming SCAN KPI framework will include data relating to rejected, redirected, or ineligible referrals. [41701/26]
Ken O'Flynn Written 9 Jun 2026 · to Health
1835. Deputy Ken O'Flynn asked the Minister for Health whether consideration is being given to establishing a nationally standardised dataset for referrals not accepted into SCAN services. [41702/26]
Ken O'Flynn Written 9 Jun 2026 · to Health
1836. Deputy Ken O'Flynn asked the Minister for Health whether any adverse incident review process exists where a person deemed ineligible for SCAN services subsequently presents in crisis, self-harms, or requires emergency intervention. [41703/26]
Ken O'Flynn Written 9 Jun 2026 · to Health
1837. Deputy Ken O'Flynn asked the Minister for Health whether SCAN services currently operate under nationally standardised eligibility criteria and whether these criteria are publicly available. [41704/26]
Ken O'Flynn Written 9 Jun 2026 · to Health
1838. Deputy Ken O'Flynn asked the Minister for Health whether any audit has been undertaken into onward referral pathways for persons not accepted into SCAN services. [41705/26]
Ken O'Flynn Written 9 Jun 2026 · to Health
1839. Deputy Ken O'Flynn asked the Minister for Health whether the Department or HSE has undertaken any modelling of the projected annual eligible population for reimbursement of tirzepatide or semaglutide for obesity treatment over the next five years. [41712/26]
Ken O'Flynn Written 9 Jun 2026 · to Health
1840. Deputy Ken O'Flynn asked the Minister for Health whether any estimate has been produced of the potential annual Exchequer cost associated with reimbursement of obesity pharmacotherapies under current licensing criteria. [41713/26]
Ken O'Flynn Written 9 Jun 2026 · to Health
1841. Deputy Ken O'Flynn asked the Minister for Health whether any national eligibility framework, prioritisation framework, or phased access model is under development for obesity pharmacotherapy reimbursement. [41714/26]
Ken O'Flynn Written 9 Jun 2026 · to Health
1842. Deputy Ken O'Flynn asked the Minister for Health whether multidisciplinary assessment, psychological screening, or behavioural intervention participation will be mandatory prior to reimbursement approval for obesity pharmacotherapies. [41715/26]
Ken O'Flynn Written 9 Jun 2026 · to Health
1843. Deputy Ken O'Flynn asked the Minister for Health whether any assessment has been undertaken of the long-term fiscal sustainability of reimbursing GLP-1 and dual agonist obesity therapies within the public health system. [41716/26]
Ken O'Flynn Written 9 Jun 2026 · to Health
1844. Deputy Ken O'Flynn asked the Minister for Health whether any formal safeguards or governance framework are being developed in relation to proposed reimbursement pathways for obesity pharmacotherapies in adolescent patients. [41717/26]
Ken O'Flynn Written 9 Jun 2026 · to Health
1845. Deputy Ken O'Flynn asked the Minister for Health whether any estimate has been produced of the projected number of adolescent patients who could potentially meet the proposed reimbursement criteria for semaglutide. [41718/26]
Ken O'Flynn Written 9 Jun 2026 · to Health
1850. Deputy Ken O'Flynn asked the Minister for Health to outline what the end-to-end process review will entail under Schedule 4 of the revised IPHA Framework Agreement; the expected terms of reference for the review; how stakeholders and members of the public will be able to feed into the review; and if she will make a statement on the matter. [41756/26]
Ken O'Flynn Written 9 Jun 2026 · to Health
1851. Deputy Ken O'Flynn asked the Minister for Health when she expects to publish the new diabetes strategy; and if she will make a statement on the matter. [41757/26]
Ken O'Flynn Written 9 Jun 2026 · to Health
1852. Deputy Ken O'Flynn asked the Minister for Health whether the HSE maintains any internal operational guidance, assessment template, decision-support document, evidential framework, or staff instruction document used in practice when determining eligibility under the treatment abroad scheme; and if so, if copies will be provided. [41759/26]
Ken O'Flynn Written 9 Jun 2026 · to Health
1853. Deputy Ken O'Flynn asked the Minister for Health whether any formal mechanism exists within the treatment abroad scheme to ensure consistency of eligibility decisions between applicants presenting with comparable clinical circumstances; and if they will outline that mechanism. [41760/26]
Ken O'Flynn Written 9 Jun 2026 · to Health
1854. Deputy Ken O'Flynn asked the Minister for Health whether any internal audit, external audit, clinical governance review, or value-for-money review has examined treatment abroad scheme eligibility decision-making processes since 2020; and if so, to provide details and publication status. [41761/26]
Ken O'Flynn Written 9 Jun 2026 · to Health
1855. Deputy Ken O'Flynn asked the Minister for Health whether the HSE maintains written evidential thresholds or documentary standards required before prior authorisation may be approved under the treatment abroad scheme; and if they will provide details. [41762/26]
Ken O'Flynn Written 9 Jun 2026 · to Health
1856. Deputy Ken O'Flynn asked the Minister for Health whether treatment abroad scheme approval decisions are subject to secondary review, peer review, multidisciplinary review, or independent oversight before final authorisation is granted. [41763/26]
Ken O'Flynn Written 9 Jun 2026 · to Health
1857. Deputy Ken O'Flynn asked the Minister for Health whether all categories of treatment funded under the treatment abroad scheme are subject to identical governance, evidential, audit, and approval standards; and if any category-specific governance arrangements exist. [41764/26]
Ken O'Flynn Written 9 Jun 2026 · to Health
1876. Deputy Ken O'Flynn asked the Minister for Health the total expenditure on agency staffing within the public health service for each year from 2020 to 2026 to date, broken down by HSE health region, staff category, and service area; and if she will make a statement on the matter. [41834/26]
Ken O'Flynn Written 9 Jun 2026 · to Health
1877. Deputy Ken O'Flynn asked the Minister for Health the number of sanctioned but unfilled permanent posts currently being covered through agency staffing arrangements within each HSE health region, broken down by grade, discipline, and service area; and if she will make a statement on the matter. [41844/26]
Ken O'Flynn Written 9 Jun 2026 · to Health
1878. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has established regional or national targets to reduce agency staffing expenditure during 2026; if so, to provide details of those targets, timelines, and oversight mechanisms; and if she will make a statement on the matter. [41845/26]
Ken O'Flynn Written 9 Jun 2026 · to Health
1879. Deputy Ken O'Flynn asked the Minister for Health the proportion of agency staffing expenditure in 2026 to date attributable to agency engagements exceeding three months, six months, and twelve months respectively, broken down by HSE health region and staff category; and if she will make a statement on the matter. [41846/26]